Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma

[1]  Susan M. Chang,et al.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). , 2009, Neuro-oncology.

[2]  P. Wen,et al.  Targeted drug therapy for meningiomas. , 2007, Neurosurgical focus.

[3]  A. Brandes,et al.  2503 ORAL Erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): results from a randomized phase II trial (EORTC 26034) , 2007 .

[4]  A. Brandes,et al.  Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034 , 2007 .

[5]  A. Brandes,et al.  Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) , 2007, British Journal of Cancer.

[6]  Susan M. Chang,et al.  Phase II study of imatinib mesylate (ST1571) for patients with recurrent meningiomas (NABTC 01-08) , 2006 .

[7]  S. Groshen,et al.  Salvage chemotherapy With CPT-11 for recurrent meningioma , 2006, Journal of Neuro-Oncology.

[8]  Mahlon D. Johnson,et al.  Mitogenic Signal Transduction Pathways in Meningiomas: Novel Targets for Meningioma Chemotherapy? , 2005, Journal of neuropathology and experimental neurology.

[9]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[10]  P. Gutin,et al.  Diagnosis and Treatment of Atypical and Anaplastic Meningiomas: A Review , 2005, Neurosurgery.

[11]  F. S. Pardo,et al.  TGF α expression in meningioma — tumor progression and therapeutic response , 1995, Journal of Neuro-Oncology.

[12]  V. Stieber,et al.  Meningioma: Current treatment options and future directions , 2004, Current treatment options in oncology.

[13]  Arie Perry,et al.  Molecular pathogenesis of meningiomas , 2004, Journal of Neuro-Oncology.

[14]  A. Bergenheim,et al.  Epidermal growth factor receptor family (EGFR, ErbB2–4) in gliomas and meningiomas , 2004, Acta Neuropathologica.

[15]  S. Groshen,et al.  Temozolomide for treatment-resistant recurrent meningioma , 2004, Neurology.

[16]  K. Lamszus,et al.  Meningioma Pathology, Genetics, and Biology , 2004, Journal of neuropathology and experimental neurology.

[17]  H. Newton,et al.  Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up , 2004, British journal of neurosurgery.

[18]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Prados,et al.  A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Hsu,et al.  MIB‐1(Ki‐67) index and transforming growth factor‐alpha (TGFα) immunoreactivity are significant prognostic predictors for meningiomas , 1998, Neuropathology and applied neurobiology.

[21]  P. Black,et al.  Expression and activation of epidermal growth factor receptors in meningiomas. , 1997, Journal of neurosurgery.

[22]  Mahlon D. Johnson,et al.  The epidermal growth factor receptor is associated with phospholipase C-γ1 in meningiomas , 1994 .

[23]  C. Arteaga,et al.  The epidermal growth factor receptor is associated with phospholipase C-gamma 1 in meningiomas. , 1994, Human pathology.

[24]  G. Schultz,et al.  Detection of epidermal growth factor and transforming growth factor alpha protein in meningiomas and other tumors of the central nervous system in human beings. , 1993, Surgery, gynecology & obstetrics.

[25]  M. Gregoriou,et al.  Epidermal growth factor receptor expression in 72 meningiomas , 1990, Cancer.

[26]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Kelly,et al.  Characterization of the epidermal growth factor receptor in human meningioma. , 1987, Cancer research.